Capricor Therapeutics Company Profile (OTCMKTS:CAPR)

About Capricor Therapeutics

Capricor Therapeutics logoCapricor Therapeutics, Inc. is a clinical-stage biotechnology company focused on the discovery, development and commercialization of therapeutics. The Company focuses on discovering, developing and commercializing regenerative medicine and large molecule products for the treatment of disease, with a primary focus on the treatment of cardiovascular diseases, including orphan indications. Its product candidate, CAP-1002, a cardiosphere-derived cell product, is being tested in the ALLSTAR Phase II clinical study on patients having suffered a myocardial infarction (MI), while the DYNAMIC clinical study is testing CAP-1002 in patients in the advanced-stage of heart failure. CAP-1002 is also being tested in the HOPE-Duchenne Phase I/II clinical study for use in connection with Duchenne muscular dystrophy-related cardiomyopathy. Cenderitide, a dual receptor natriuretic peptide agonist, is being tested in a Phase II clinical study. Exosomes are nano-sized, membrane-enclosed vesicles.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: OTCMKTS
  • Symbol: CAPR
  • CUSIP:
Key Metrics:
  • Previous Close: $3.11
  • 50 Day Moving Average: $2.5573
  • 200 Day Moving Average: $3.0878
  • 52-Week Range: $1.91 - $5.40
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -3.40
  • P/E Growth: 0.0000
  • Market Cap: $66.13M
  • Outstanding Shares: 21,399,000
Additional Links:
Companies Related to Capricor Therapeutics:

Analyst Ratings

Consensus Ratings for Capricor Therapeutics (OTCMKTS:CAPR) (?)
Ratings Breakdown: 3 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $13.00

Analysts' Ratings History for Capricor Therapeutics (OTCMKTS:CAPR)
Show:
DateFirmActionRatingPrice TargetDetails
2/13/2017Rodman & RenshawInitiated CoverageBuy$14.00View Rating Details
10/20/2016Roth CapitalSet Price TargetBuy$12.00View Rating Details
7/6/2016HC WainwrightInitiated CoverageBuy$13.00View Rating Details
(Data available from 2/22/2015 forward)

Earnings

Earnings History for Capricor Therapeutics (OTCMKTS:CAPR)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/15/2017        
8/15/2016Q2($0.24)($0.26)$1.21 millionViewListenView Earnings Details
5/12/2016Q116($0.19)($0.26)$1.10 millionViewListenView Earnings Details
3/17/2016Q415($0.19)($0.21)$1.10 millionViewN/AView Earnings Details
11/12/2015Q315($0.26)($0.18)$1.10 millionViewN/AView Earnings Details
8/13/2015Q215($0.26)($0.19)$1.10 millionViewN/AView Earnings Details
5/12/2015($0.14)($0.23)ViewN/AView Earnings Details
4/15/2015($0.14)($0.16)ViewN/AView Earnings Details
11/14/2014($0.22)($0.13)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Capricor Therapeutics (OTCMKTS:CAPR)
Current Year EPS Consensus Estimate: $-1.11 EPS
Next Year EPS Consensus Estimate: $-0.91 EPS

Dividends

Dividend History for Capricor Therapeutics (OTCMKTS:CAPR)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Capricor Therapeutics (OTCMKTS:CAPR)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/21/2016Sinai Medical Center CedarsMajor ShareholderBuy312,500$3.20$1,000,000.00View SEC Filing  
3/16/2016Anthony BergmannVPBuy2,030$2.40$4,872.00View SEC Filing  
3/16/2016Karen KrasneyEVPBuy4,060$2.40$9,744.00View SEC Filing  
3/16/2016Leland GershellCFOBuy2,100$2.40$5,040.00View SEC Filing  
3/16/2016Linda MarbanCEOBuy10,152$2.40$24,364.80View SEC Filing  
3/16/2016Louis J GrasmickDirectorBuy91,369$2.40$219,285.60View SEC Filing  
3/16/2016Sinai Medical Center CedarsMajor ShareholderBuy416,666$2.40$999,998.40View SEC Filing  
8/20/2015Louis J. GrasmickDirectorBuy11,900$4.11$48,909.00View SEC Filing  
8/19/2015Eduardo Marbanmajor shareholderBuy18,400$4.36$80,224.00View SEC Filing  
1/21/2015Joshua A KazamDirectorBuy7,096$3.52$24,977.92View SEC Filing  
1/21/2015Sinai Medical Center CedarsMajor ShareholderBuy851,546$3.52$2,997,441.92View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Capricor Therapeutics (OTCMKTS:CAPR)
DateHeadline
News IconCapricor Therapeutics cancels license pact with Mayo Clinic relating to natriuretic peptide receptor agonists including Cenderitide (OTCMKTS:CAPR)
pharmabiz.com - February 18 at 10:08 AM
News IconCapricor Therapeutics Inc CAPR Financial and Strategic SWOT Analysis Review [Updated: 13012017] Prices from USD $300 (OTCMKTS:CAPR)
www.bioportfolio.com - February 18 at 10:08 AM
investopedia.com logoCapricor Ends Cenderitide Heart Drug Program (CAPR) (OTCMKTS:CAPR)
www.investopedia.com - February 18 at 10:08 AM
News IconMarket Spotter: Focusing on These Shares Capricor Therapeutics, Inc. (NASDAQ:CAPR) - Piedmont Register (OTCMKTS:CAPR)
piedmontregister.com - February 17 at 6:02 PM
reuters.com logoBRIEF-Capricor Therapeutics provides update on Natriuretic Peptide program - Reuters (OTCMKTS:CAPR)
www.reuters.com - February 17 at 6:02 PM
marketexclusive.com logoCAPRICOR THERAPEUTICS, INC. (NASDAQ:CAPR) Files An 8-K Termination of a Material Definitive Agreement - Market Exclusive (OTCMKTS:CAPR)
marketexclusive.com - February 17 at 6:02 PM
prnewswire.com logoCapricor Therapeutics Provides Update on Natriuretic Peptide Program - PR Newswire (press release) (OTCMKTS:CAPR)
www.prnewswire.com - February 17 at 6:02 PM
investopedia.com logoCapricor Therapeutics Ends Heart Drug Development (OTCMKTS:CAPR)
www.investopedia.com - February 17 at 6:02 PM
streetinsider.com logoCapricor Therapeutics (CAPR) Offer Update on Natriuretic Peptide Program (OTCMKTS:CAPR)
www.streetinsider.com - February 16 at 9:13 PM
4-traders.com logoCAPRICOR THERAPEUTICS, INC. : Termination of a Material Definitive Agreement (form 8-K) (OTCMKTS:CAPR)
www.4-traders.com - February 16 at 9:13 PM
finance.yahoo.com logoCapricor Therapeutics Provides Update on Natriuretic Peptide Program (OTCMKTS:CAPR)
finance.yahoo.com - February 16 at 9:13 PM
finance.yahoo.com logo5:02 pm Capricor Therapeutics terminates license agreement with the Mayo Clinic relating to natriuretic peptide receptor agonists, including Cenderitide (OTCMKTS:CAPR)
finance.yahoo.com - February 16 at 9:13 PM
biz.yahoo.com logoCAPRICOR THERAPEUTICS, INC. Files SEC form 8-K, Termination of a Material Definitive Agreement (OTCMKTS:CAPR)
biz.yahoo.com - February 16 at 9:13 PM
biz.yahoo.com logoCAPRICOR THERAPEUTICS, INC. Files SEC form 8-K, Termination of a Material Definitive Agreement (OTCMKTS:CAPR)
biz.yahoo.com - February 16 at 9:13 PM
finance.yahoo.com logoCapricor Therapeutics to Present at the 2017 BIO CEO and Investor Conference (OTCMKTS:CAPR)
finance.yahoo.com - February 7 at 5:09 PM
News IconTony Coles, M.D., Elected to Regeneron Board of Directors (OTCMKTS:CAPR)
www.bio-medicine.org - January 31 at 4:30 PM
News IconBrokers Change Their Target Price On Morgan Stanley (NYSE:MS) (OTCMKTS:CAPR)
itapunta.com - January 24 at 4:42 PM
News IconMyocardial Infarction Therapeutics Global Market Key Developments, Outlook, Analysis & Forecast to 2022 (OTCMKTS:CAPR)
www.emailwire.com - January 11 at 2:54 AM
News IconCapricor Therapeutics Inc CAPR Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (OTCMKTS:CAPR)
www.bioportfolio.com - January 6 at 2:37 AM
News IconEndeavour Silver Corporation (NYSE:EXK) Broker Price Targets For The Coming Week (OTCMKTS:CAPR)
flapship.com - December 31 at 9:12 PM
capitalcube.com logoETFs with exposure to Capricor Therapeutics, Inc. : December 13, 2016 (OTCMKTS:CAPR)
www.capitalcube.com - December 13 at 4:50 PM
News IconCedars-Sinai receives $7.3 million grant to test safety of novel cell-based therapy in treating PAH (OTCMKTS:CAPR)
www.news-medical.net - December 7 at 5:37 AM
News IconCapricor Therapeutics, Inc. CAPR Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (OTCMKTS:CAPR)
www.bioportfolio.com - December 2 at 9:30 PM
News IconMyocardial Infarction Therapeutics Global Market, By Product & Data Validation, Analysis and Forecast 2022 (OTCMKTS:CAPR)
empowerednews.net - December 1 at 4:10 PM
News IconGlobal Marrow Transplant Rejection – Pipeline Review, H2 2016 (OTCMKTS:CAPR)
empowerednews.net - November 30 at 4:09 PM
finance.yahoo.com logoCAPRICOR THERAPEUTICS, INC. Financials (OTCMKTS:CAPR)
finance.yahoo.com - November 23 at 8:54 PM
News IconMuscular Dystrophy Pipeline Market Global Analysis and Therapeutics Development for H2 2016 (OTCMKTS:CAPR)
www.bio-medicine.org - November 22 at 3:34 PM
finance.yahoo.com logoCapricor Therapeutics to Present at the 28th Annual Piper Jaffray Healthcare Conference (OTCMKTS:CAPR)
finance.yahoo.com - November 21 at 8:58 AM
capitalcube.com logoETFs with exposure to Capricor Therapeutics, Inc. : November 16, 2016 (OTCMKTS:CAPR)
www.capitalcube.com - November 16 at 3:58 PM
biz.yahoo.com logoCAPRICOR THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report (OTCMKTS:CAPR)
biz.yahoo.com - November 14 at 9:38 PM
capitalcube.com logoCapricor Therapeutics, Inc. :CAPR-US: Earnings Analysis: Q3, 2016 By the Numbers : November 14, 2016 (OTCMKTS:CAPR)
www.capitalcube.com - November 14 at 4:11 PM
News IconCapricor to expand CAP-1002 clinical development programme in DMD to evaluate peripheral & respiratory muscle function (OTCMKTS:CAPR)
pharmabiz.com - November 14 at 6:43 AM
News IconCapricor Therapeutics Announces Plans to Expand Clinical Development Program in Duchenne Muscular Dystrophy to Evaluate Peripheral and (OTCMKTS:CAPR)
www.biomedreports.com - November 12 at 4:08 PM
finance.yahoo.com logoCapricor Therapeutics Announces Plans to Expand Clinical Development Program in Duchenne Muscular Dystrophy … (OTCMKTS:CAPR)
finance.yahoo.com - November 12 at 4:08 PM
News IconCapricor Therapeutics Reports Third Quarter 2016 Financial Results and Provides Corporate Update (OTCMKTS:CAPR)
ih.advfn.com - November 12 at 4:08 PM
sg.finance.yahoo.com logoCapricor reports 3Q loss (OTCMKTS:CAPR)
sg.finance.yahoo.com - November 10 at 10:04 PM
publicnow.com logoInvestor Calendar Invites You to the Capricor Therapeutics Third Quarter 2016 Business Update and Financial Results Conference Call and Webcast on Thursday, November 10, 2016 (OTCMKTS:CAPR)
www.publicnow.com - November 9 at 8:58 PM
finance.yahoo.com logoCapricor Therapeutics to Hold Third Quarter 2016 Business Update and Financial Results Conference Call … (OTCMKTS:CAPR)
finance.yahoo.com - November 3 at 9:06 PM
publicnow.com logoCapricor Therapeutics to Hold Third Quarter 2016 Business Update and Financial Results Conference Call and Webcast on Thursday, November 10 at 5:00 p.m. ET (OTCMKTS:CAPR)
www.publicnow.com - November 3 at 1:42 PM
reuters.com logoBRIEF-Capricor Therapeutics gives 12-month results from Dynamic (OTCMKTS:CAPR)
www.reuters.com - November 1 at 8:08 AM
publicnow.com logoCapricor Therapeutics Presents Positive 12-Month Results from DYNAMIC at TCT 2016 (OTCMKTS:CAPR)
www.publicnow.com - October 31 at 10:00 AM
4-traders.com logoCapricor Therapeutics : CAPR) Trades Higher on News of $4.2M Grant from National Institutes of Health (OTCMKTS:CAPR)
www.4-traders.com - October 20 at 3:34 PM
publicnow.com logoCapricor Therapeutics Awarded Up to $4.2 Million from National Institutes of Health to Evaluate Exosomes for Hypoplastic Left Heart Syndrome (OTCMKTS:CAPR)
www.publicnow.com - October 20 at 8:53 AM
News IconCapricor Therapeutics completes patient enrollment in phase II ALLSTAR trial (OTCMKTS:CAPR)
www.pharmabiz.com - October 7 at 8:58 AM
proactiveinvestors.co.uk logoServices data surprise provides extra fillip to stocks (OTCMKTS:CAPR)
www.proactiveinvestors.co.uk - October 5 at 4:21 PM
bizjournals.com logoExosome Diagnostic and Therapeutic Market Would Reach $367 Million by 2022, Globally - Allied Market Research (OTCMKTS:CAPR)
www.bizjournals.com - October 5 at 4:21 PM
streetinsider.com logoCapricor Therapeutics (CAPR) Completes Patient Enrollment in Phase II ALLSTAR Trial (OTCMKTS:CAPR)
www.streetinsider.com - October 5 at 9:08 AM
biz.yahoo.com logoCAPRICOR THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits (OTCMKTS:CAPR)
biz.yahoo.com - October 5 at 9:08 AM
publicnow.com logoCapricor Therapeutics Completes Enrollment in Phase II ALLSTAR Clinical Trial (OTCMKTS:CAPR)
www.publicnow.com - October 5 at 9:08 AM
publicnow.com logoCapricor Therapeutics to Present at Upcoming Investor Conferences (OTCMKTS:CAPR)
www.publicnow.com - September 29 at 8:57 AM

Social

What is Capricor Therapeutics' stock symbol?

Capricor Therapeutics trades on the OTCMKTS under the ticker symbol "CAPR."

Where is Capricor Therapeutics' stock going? Where will Capricor Therapeutics' stock price be in 2017?

3 equities research analysts have issued twelve-month price targets for Capricor Therapeutics' stock. Their forecasts range from $12.00 to $14.00. On average, they expect Capricor Therapeutics' share price to reach $13.00 in the next twelve months.

When will Capricor Therapeutics announce their earnings?

Capricor Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, March, 15th 2017.

Who owns Capricor Therapeutics stock?

Capricor Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional investors include Brown Advisory Inc. (0.33%) and Frontier Wealth Management LLC (0.22%). Company insiders that own Capricor Therapeutics stock include Anthony Bergmann, Eduardo Marban, Karen Krasney, Leland Gershell, Linda Marban, Louis J Grasmick and Sinai Medical Center Cedars.

How do I buy Capricor Therapeutics stock?

Shares of Capricor Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Capricor Therapeutics stock cost?

One share of Capricor Therapeutics stock can currently be purchased for approximately $3.09.

Capricor Therapeutics (OTCMKTS:CAPR) Chart for Wednesday, February, 22, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Capricor Therapeutics (OTCMKTS:CAPR)

Earnings History Chart

Earnings by Quarter for Capricor Therapeutics (OTCMKTS:CAPR)

Dividend History Chart

Dividend Payments by Quarter for Capricor Therapeutics (OTCMKTS:CAPR)

Last Updated on 2/22/2017 by MarketBeat.com Staff